Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?

Sandisk, Moderna and Dell shares have risen about 600%, 550% and more than 350%, respectively, this year, prompting the article to weigh continued growth against correction risk. Sandisk benefits from strong AI-related memory demand and constrained supply; Dell reported 58% revenue growth to $47 billion as demand for AI servers increased. Moderna rallied after encouraging cancer-vaccine trial results with Merck, but the treatment is not approved, and the author questions whether the gains in all three stocks are sustainable and suggests trimming positions.

Analysis

The key risk is not the stocks’ year-to-date gains themselves; it is that each rally embeds a different, potentially fragile earnings denominator. For Sandisk, high memory prices and tight supply can lift near-term earnings while making a low forward multiple look deceptively reassuring: a supply response or weaker orders could compress both earnings and the multiple. Watch pricing, inventory, and customer lead times—not AI headlines alone. Samsung Electronics and SK Hynix are relevant supply-side checks.

Dell’s exposure is more indirect: AI server demand depends on customers sustaining infrastructure budgets, while component availability and costs can affect delivery and profitability. Strong revenue alone does not settle whether growth converts into durable margins and cash flow. Track orders/backlog, margins, and cash conversion alongside hyperscaler spending; a slowdown in customer commitments is a more useful warning than a broad market pullback.

Moderna is a distinct, event-driven case, not an AI momentum trade. The partnership with Merck may validate the program, but trial durability, eventual regulatory review, commercial uptake, and economics determine value. Without those details, neither the rally nor a bearish call can be underwritten from the trial headline alone. Near term, positioning and broad risk appetite can dominate; over 1–3 months, company disclosures and clinical updates matter; over 6–18 months, memory-cycle normalization, AI capex returns, and clinical/regulatory progress are the thesis tests. The contrarian point: trimming solely because a stock rose sharply can surrender further earnings upgrades; the stronger discipline is to reduce exposure when operating indicators—not price alone—roll over.

Key Decisions for Investors

• SNDK: Avoid an outright short based only on the rally. Consider staged profit-taking or a smaller position, and reassess if memory pricing, orders, or customer lead times weaken. The thesis is falsified if tight supply and pricing persist while earnings estimates continue to rise.
• DELL: Keep AI-server exposure sized to withstand a capex pause; do not treat revenue growth as proof of durable economics. Monitor backlog/orders, profitability, and cash conversion. A deterioration in these measures or customer spending plans would support further trimming; sustained orders and stable economics would argue against it.
• Relative-value watch: If memory pricing and supply loosen while Dell orders remain resilient, evaluate a SNDK-underweight/DELL-overweight pair rather than a broad technology short. Confirm with memory-market indicators and Dell operating disclosures; Dell’s own component-cost exposure and AI-spending sensitivity can also break the pair.
• MRNA: Treat as a clinical-event position, not a valuation call from share performance. Verify trial follow-up, endpoint durability, regulatory path, and the partners’ commercial economics before adding; avoid an unhedged short ahead of clinical or regulatory catalysts. Merck’s participation does not establish how value is divided.